Chlamydia is a common sexually transmitted infection that can occur without noticeable symptoms. Testing helps sexually active adults identify the infection and receive appropriate treatment when necessary. Screening recommendations depend on age, sexual activity, pregnancy status, and individual risk factors. Understanding when to get tested, which tests are available, and when repeat screening.
Chlamydia is caused by the bacterium Chlamydia trachomatis and can affect the genital tract, rectum, and throat. Because many infections do not cause symptoms, individuals may have chlamydia without realizing it. Regular screening based on established medical recommendations can help identify infections early. Testing decisions should consider age, sexual history, pregnancy, and exposure to sexually transmitted infections.
Screening recommendations vary according to individual circumstances and local clinical guidelines. In the United States, the Centers for Disease Control and Prevention (CDC) recommends annual screening for sexually active women younger than 25 years. Women aged 25 and older should also be screened when they have increased risk factors. Recommendations for men depend on their sexual practices, risk factors, and the populations in which they receive care.
Healthcare professionals can help determine the appropriate testing schedule based on personal circumstances and possible exposure.
Women younger than 25: Annual screening is recommended for sexually active women in this age group.
Women aged 25 and older: Testing is recommended when risk factors are present, including a new sexual partner, multiple partners, or a partner with an STI.
Men who have sex with men: At least annual screening is recommended at sites of sexual contact, with testing every three to six months considered for individuals at increased risk.
Pregnant individuals: Screening is recommended during early pregnancy for those younger than 25 or those with increased risk. Repeat testing later in pregnancy may be recommended when risk continues.
Individuals with possible exposure: Anyone whose partner has been diagnosed with chlamydia should seek prompt medical advice about testing and treatment, regardless of symptoms.
Chlamydia testing commonly uses a nucleic acid amplification test (NAAT), which detects the genetic material of the bacteria. Depending on the exposure site and the test used, samples may include urine or swabs collected from the vagina, cervix, urethra, rectum, or throat. A healthcare professional can recommend the appropriate sample based on sexual practices and symptoms.
Testing does not always require a physical examination. Some services offer self-collected swabs or urine testing, depending on availability and local procedures.
Urine testing: A urine sample can detect genital chlamydia, particularly when the appropriate collection instructions are followed.
Swab testing: Vaginal, cervical, rectal, or throat swabs may be used when infection at those sites is possible.
Repeat screening: People treated for chlamydia should generally be retested about three months later because reinfection is common. This is different from a routine test of cure.
Treatment and partner care: Chlamydia is treatable with antibiotics prescribed by a healthcare professional. Recent sexual partners may also need evaluation and treatment to prevent reinfection.
Reducing transmission: Avoid sexual activity for seven days after single-dose treatment or until a seven-day treatment course is completed, and until partners have been treated as advised by a clinician.
Individuals who experience pelvic pain, testicular pain, unusual discharge, or pain during urination should seek medical evaluation. Early testing and appropriate treatment can reduce the risk of complications. Screening intervals and recommendations may differ by country, so individuals should follow local clinical guidance and discuss personal risk factors with a qualified healthcare professional.